EpiPen. HIV Drugs. Hep C Treatment. Insulin.

The list of drugs that have grabbed headlines for dizzyingly high prices are just the tip of the iceberg. Pharmaceutical companies’ habit of pushing the limits on drug prices is costing states like California billions and driving up the cost of healthcare.

Enough is enough. It’s time for solutions.

California Takes On Out-of-Control Prescription Drug Pricing

SB 17 BRINGS PHARMA’S PRICING TACTICS OUT OF THE SHADOWS

The pharmaceutical industry spent years stalling transparency legislation in the state legislature but, California families made progress in 2017 with the passage of SB 17. There’s more to be done, but this landmark law is paving the way for more sustainable, affordable prescription drug prices.

 

AB 824 SEEKS TO END PHARMA’S ANTI-COMPETITIVE PRICING TACTICS

Pay-for-delay agreements, also known as reverse payment settlements, occur when major brand-name pharmaceutical companies pay off generic manufacturers to delay entering their lower-priced generic versions of the drug into the market for a set period of time. Pay-for-delay agreements take money from patient pockets to unfairly increase drug company profits. AB 824 (Wood) is currently making its way through California’s Capitol. The law will give Attorney General Becerra greater tools to crack down on pay-for-delay schemes — bringing more generic drugs into the marketplace to ensure competition helps all Californians have access to more affordable health care. Read more about Pay-for-Delay.

Stay Informed

Stay up to date on the fight against runaway prescription drug prices.

According to an @ICER review, "the norm in the United States has been for most pharmaceutical manufacturers to increase prices year after year” … and “found that the price increases lacked justification.”
https://t.co/AdiaHnbOiq https://t.co/4xNYKVju8C

Thanks to the first @CA_OSHPD report of its kind, we now know that one cancer treatment drug increased its price by 75% and no reason for this increase was provided by the manufacturer. Find out more: https://t.co/zYkqKtNrV7

Californians shouldn’t have to choose between paying their rent or affording lifesaving prescription drugs. Learn more about skyrocketing prescription drug prices: https://t.co/UJhiD8tHXZ https://t.co/nHipLCIheu

California patients had a big win against big pharma in 2019! AB 824 will help make prescription drugs more affordable by bringing more lower cost generic drugs into the market. https://t.co/D0APEty8HX

Transparency in Drug Pricing

Health coverage protects us from most of Big Pharma’s price gouging, but drugs with six-figure price tags drive up the cost of care for everyone.
In 2017, California passed SB 17 to bring pharmaceutical companies’ pricing tactics out of the dark and begin to address the growing affordability crisis. The bill, which will serve as a model for the nationwide push to address rising prescription drug prices, came on the tails of truly outrageous price hikes, like Mylan’s decision to needlessly up the price of EpiPens by nearly 500 percent and Gilead Sciences’ pricing of a lifesaving treatment at $1,000 per pill. While examples like these are widely known, the pharmaceutical industry has been quietly upping the price of old and new drugs alike. This destructive practice has led prescription drug prices to become the fastest growing portion of the health care dollar.

SB 17 is now:

Giving A Heads
Up On
Price Hikes

Price Hike Alerts - Icon
Drug companies will give payers notice of major price increases for the most expensive drugs

Helping Plan
For
Increases

Planning for Increases - Icon
Payers can plan ahead for significant price increases on medications

Providing Data
To Inform
Solutions

Informed Solutions - Icon
Lawmakers can review historical trends on drug costs to inform solutions

Creating
Public
Accountability

Public Accountability - Icon
Public will have access to basic information on what drives price hikes and drug spending